medcelerator · clinician one-pager
New Oral Treatment for Multiple Myeloma After Prior Therapy
Zenbexus (iberdomide) — first labelled CELMoD for adults with multiple myeloma after ≥1 prior line
FDA Approved · United States · September 7, 2026
Condition: Multiple Myeloma
Who this is for
This is for adults with multiple myeloma who have already had at least one prior treatment that included a proteasome inhibitor and an immunomodulatory drug, and who may be candidates for a labelled US oral CELMoD used with subcutaneous daratumumab and dexamethasone. It explains the FDA accelerated label, REMS pregnancy rules, blood-clot and infection watchpoints, the EXCALIBER-RRMM trial numbers behind the approval, and how to talk with a myeloma clinician — without treating a completed enrolment window or a foreign pack as the care plan. Confirmatory progression-free survival work is still ongoing; authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/221075Orig1s000lbl.pdf
United States · Prescription with safety programme (REMS)
ZENBEXUS REMS (restricted distribution)
https://www.zenbexusrems.com
United States · Recruiting clinical trial
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Combination or different setting. Iberdomide +/- dexamethasone in smoldering myeloma, not relapsed myeloma (phase 2).
https://clinicaltrials.gov/study/NCT04776395
United States · Recruiting clinical trial
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Combination or different setting. Iberdomide + daratumumab + carfilzomib + dexamethasone in relapsed myeloma (phase 2); label adds carfilzomib.
https://clinicaltrials.gov/study/NCT05896228
United States · Recruiting clinical trial
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Combination or different setting. Iberdomide + daratumumab as maintenance after transplant (phase 2).
https://clinicaltrials.gov/study/NCT06107738
Search all trials on ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=multiple%20myeloma&intr=iberdomide&aggFilters=status:rec
Possible routes (not confirmed)
United States · Company expanded-access programme · Applicability unknown
BMS individual-patient expanded access NCT07434960
EAP record lists no sites and was last verified 2026-02, before FDA approval; new intake not stated.
https://clinicaltrials.gov/study/NCT07434960
United States · Not yet recruiting clinical trial · Applicability unknown
Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
Trial not yet recruiting (ClinicalTrials.gov status: not yet taking patients).
https://clinicaltrials.gov/study/NCT07601100
United States · Not yet recruiting clinical trial · Applicability unknown
Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Trial not yet recruiting (ClinicalTrials.gov status: not yet taking patients).
https://clinicaltrials.gov/study/NCT07727668
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/zenbexus-iberdomide